Citadel Advisors
OKUR

Citadel Advisors’s OnKure Therapeutics OKUR Stock Holding History

Citadel Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41M Buy
1,187,047
+1,149,460
+3,058% +$4.93M ﹤0.01% 4581
2026
Q1 		$156K Sell
37,587
-185,538
-83% -$573K ﹤0.01% 11650
2025
Q4 		$647K Sell
223,125
-793,488
-78% -$2.38M ﹤0.01% 8392
2025
Q3 		$2.8M Sell
1,016,613
-72,697
-7% -$180K ﹤0.01% 5428
2025
Q2 		$2.6M Buy
1,089,310
+21,206
+2% +$55.6K ﹤0.01% 5219
2025
Q1 		$4.44M Sell
1,068,104
-6,210
-0.6% -$34.9K ﹤0.01% 4075
2024
Q4 		$8.78M Buy
1,074,314
+1,065,023
+11,463% +$16.1M ﹤0.01% 3144
2024
Q3 		$158K Buy
9,291
+8,200
+752% +$121K ﹤0.01% 10499
2024
Q2 		$16.5K Sell
1,091
-5,524
-84% -$93.6K ﹤0.01% 12786
2024
Q1 		$110K Buy
6,615
+5,648
+584% +$93.2K ﹤0.01% 11224
2023
Q4 		$15.5K Sell
967
-491
-34% -$30.6K ﹤0.01% 12840
2023
Q3 		$111K Sell
1,458
-1,594
-52% -$108K ﹤0.01% 10760
2023
Q2 		$200K Buy
+3,052
New +$246K ﹤0.01% 9890
2022
Q4 		– Sell
-14,615
Closed -$490K – 15567
2022
Q3 		$490K Sell
14,615
-2,644
-15% -$86.8K ﹤0.01% 8495
2022
Q2 		$457K Buy
+17,259
New +$402K ﹤0.01% 8841

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's OKUR Position: Q2 2026 in Review

Citadel Advisors increased its OnKure Therapeutics (OKUR) stake by 3,058% in Q2 2026, buying an estimated $4.93M and bringing the position to 1,187,047 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #4581.

Citadel Advisors first reported a position in OKUR in Q2 2022 and has held it in 15 quarters since. The position peaked at $8.78M in Q4 2024. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Citadel Advisors held 1,187,047 shares of OnKure Therapeutics worth $5.41M as of Q2 2026.
  • Citadel Advisors bought 1,149,460 OnKure Therapeutics shares in Q2 2026, an estimated $4.93M.
  • OnKure Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4581 holding.
  • Citadel Advisors first reported a position in OnKure Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Citadel Advisors's OnKure Therapeutics position peaked at $8.78M in Q4 2024.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.